Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.

Details

Ressource 1Download: 36914788_BIB_753571631919.pdf (411.11 [Ko])
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_753571631919
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.
Journal
Cardiovascular and interventional radiology
Author(s)
Maleux G., Albrecht T., Arnold D., Bargellini I., Cianni R., Helmberger T., Kolligs F., Munneke G., Peynircioglu B., Sangro B., Schaefer N., Pereira H., Zeka B., de Jong N., Bilbao J.I.
Working group(s)
CIRT Principal Investigators
Contributor(s)
Albrecht T., D'Archambeau O., Balli T., Bilgic S., Bloom A., Cioni R., Fischbach R., Flamen P., Gerard L., Golfieri R., Grözinger G., Katoh M., Koehler M., Kröger J.R., Kuhl C., Orsi F., Özgün M., Reimer P., Ronot M., Schmid A., Vit A., Maleux G., Sangro B., Pech M., Helmberger T., Cianni R., Pfammatter T.
ISSN
1432-086X (Electronic)
ISSN-L
0174-1551
Publication state
Published
Issued date
07/2023
Peer-reviewed
Oui
Volume
46
Number
7
Pages
852-867
Language
english
Notes
Publication types: Observational Study ; Journal Article
Publication Status: ppublish
Abstract
Using data collected in the prospective observational study CIRSE Registry for SIR-Spheres Therapy, the present study aimed at identifying predictors of adverse events (AEs) following transarterial radioembolization (TARE) with Yttrium-90 resin microspheres for liver tumours.
We analysed 1027 patients enrolled between January 2015 and December 2017 and followed up for 24 months. Four hundred and twenty-two patients with hepatocellular carcinoma (HCC), 120 with intrahepatic carcinoma (ICC), 237 with colorectal liver metastases and 248 with liver metastases from other primaries were included. Prognostic factors were calculated with a univariable analysis by using the overall AEs burden score (AEBS).
All-cause AEs were reported in 401/1027 (39.1%) patients, with AEs associated with TARE, such as abdominal pain (16.6%), fatigue (17%), and nausea (11.7%) reported most frequently. Grade 3 or higher AEs were reported in 92/1027 (9%) patients. Reports on grade ≥ 3 gastrointestinal ulcerations (0.4%), gastritis (0.3%), radiation cholecystitis (0.2%) or radioembolization-induced liver disease (0.5%) were uncommon. Univariable analysis showed that in HCC, AEBS increased for Eastern Cooperative Oncology Group (ECOG) 0 (p = 0.0045), 1 tumour nodule (0.0081), > 1 TARE treatment (p = 0.0224), no prophylactic embolization (p = 0.0211), partition model dosimetry (p = 0.0007) and unilobar treatment target (0.0032). For ICC, > 1 TARE treatment was associated with an increase in AEBS (p = 0.0224), and for colorectal liver metastases, ECOG 0 (p = 0.0188), > 2 prior systemic treatments (p = 0.0127), and 1 tumour nodule (p = 0.0155) were associated with an increased AEBS.
Our study confirms that TARE is a safe treatment with low toxicity and a minimal impact on quality of life.
Keywords
Humans, Carcinoma, Hepatocellular/radiotherapy, Carcinoma, Hepatocellular/pathology, Liver Neoplasms/therapy, Microspheres, Quality of Life, Yttrium Radioisotopes/adverse effects, Embolization, Therapeutic/adverse effects, Embolization, Therapeutic/methods, Europe/epidemiology, Colorectal Neoplasms/therapy
Pubmed
Web of science
Open Access
Yes
Create date
20/03/2023 11:43
Last modification date
23/01/2024 8:28
Usage data